|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: Globocan estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Sargent D, Sobrero A, Grothey A, O'Connell
MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C,
et al: Evidence for cure by adjuvant therapy in colon cancer:
Observations based on individual patient data from 20,898 patients
on 18 randomized trials. J Clin Oncol. 27:872–877. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maughan TS, Adams RA, Smith CG, Meade AM,
Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL,
et al: Addition of cetuximab to oxaliplatin-based first-line
combination chemotherapy for treatment of advanced colorectal
cancer: Results of the randomised phase 3 mrc coin trial. Lancet.
377:2103–2114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Larsen AK, Poindessous V, Ouaret D, El
Ouadrani K, Megalophonos VF, Batistella A, Petitprez A, Escargueil
AE, Tournigand C and De Gramont A: Feasibility of combining EGFR-
and VEGF(R)-targeted agents in colorectal cancer. J Clin Oncol. 29
(4_suppl):S4432011. View Article : Google Scholar
|
|
6
|
Chibaudel B, Henriques J, Rakez M, Brenner
B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A,
Shim K, Jonker D, et al: Association of bevacizumab plus
oxaliplatin-based chemotherapy with disease-free survival and
overall survival in patients with stage II colon cancer: A
secondary analysis of the avant trial. JAMA Netw Open.
3:e20204252020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cutroneo PM, Giardina C, Ientile V,
Potenza S, Sottosanti L, Ferrajolo C, Trombetta CJ and Trifirò G:
Overview of the safety of anti-VEGF drugs: Analysis of the Italian
spontaneous reporting system. Drug Saf. 40:1131–1140. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Passaro A, Jänne PA, Mok T and Peters S:
Overcoming therapy resistance in EGFR-mutant lung cancer. Nat
Cancer. 2:377–391. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H,
Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al: TATTON: A
multi-arm, phase Ib trial of osimertinib combined with selumetinib,
savolitinib, or durvalumab in egfr-mutant lung cancer. Ann Oncol.
31:507–516. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang T, Huang X, Zhang G, Hong Z, Bai X
and Liang T: Advantages of targeting the tumor immune
microenvironment over blocking immune checkpoint in cancer
immunotherapy. Signal Transduct Target Ther. 6:722021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sedighzadeh SS, Khoshbin AP, Razi S,
Keshavarz-Fathi M and Rezaei N: A narrative review of
tumor-associated macrophages in lung cancer: Regulation of
macrophage polarization and therapeutic implications. Transl Lung
Cancer Res. 10:1889–1916. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized m2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Müller E, Christopoulos PF, Halder S,
Lunde A, Beraki K, Speth M, Øynebråten I and Corthay A: Toll-like
receptor ligands and interferon-γ synergize for induction of
antitumor m1 macrophages. Front Immunol. 8:13832017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jing M, Ma M, Zhang M, Mei Y, Wang L,
Jiang Y, Li J, Song R, Yang Z, Pu Y, et al: The photothermal effect
induces m1 macrophage-derived tnf-α-type exosomes to inhibit
bladder tumor growth. Chem Eng J. 498:1550232024. View Article : Google Scholar
|
|
17
|
Aslam M, Ashfaq-Khan M, Qureshi A, Celik
S, Werle J-T, Senkowski M, Kim YO, KAPS L and Schuppan D:
Fri-453-rapamycin promotes tumoricidal immunity in murine HCC by
inducing M1-type macrophages and dentritic cells polarization and
enhancement of cytotoxic T-cells. J Hepatol. 70:e5952019.
View Article : Google Scholar
|
|
18
|
Han Y, Sun J, Yang Y, Liu Y, Lou J, Pan H,
Yao J and Han W: TMP195 exerts antitumor effects on colorectal
cancer by promoting M1 macrophages polarization. Int J Biol Sci.
18:5653–5666. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Griess B, Mir S, Datta K and
Teoh-Fitzgerald M: Scavenging reactive oxygen species selectively
inhibits M2 macrophage polarization and their pro-tumorigenic
function in part, via Stat3 suppression. Free Radic Biol Med.
147:48–60. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cassetta L and Pollard JW:
Tumor-associated macrophages. Curr Biol. 30:R246–R248. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng Y, Ren S, Zhang Y, Liu S, Meng L,
Liu F, Gu L, Ai N and Sang M: Circular RNA circWWC3 augments breast
cancer progression through promoting M2 macrophage polarization and
tumor immune escape via regulating the expression and secretion of
IL-4. Cancer Cell Int. 22:2642022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee YH, Martin-Orozco N, Zheng P, Li J,
Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, et al:
Inhibition of the B7-H3 immune checkpoint limits tumor growth by
enhancing cytotoxic lymphocyte function. Cell Res. 27:1034–1045.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kee JY, Ito A, Hojo S, Hashimoto I,
Igarashi Y, Tsuneyama K, Tsukada K, Irimura T, Shibahara N,
Takasaki I, et al: CXCL16 suppresses liver metastasis of colorectal
cancer by promoting TNF-α-induced apoptosis by tumor-associated
macrophages. BMC Cancer. 14:9492014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brigati C, Noonan DM, Albini A and Benelli
R: Tumors and inflammatory infiltrates: Friends or foes? Clin Exp
Metastasis. 19:247–258. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Locati M, Curtale G and Mantovani A:
Diversity, mechanisms, and significance of macrophage plasticity.
Annu Rev Pathol. 15:123–147. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Inagaki K, Kunisho S, Takigawa H, Yuge R,
Oka S, Tanaka S, Shimamoto F, Chayama K and Kitadai Y: Role of
tumor-associated macrophages at the invasive front in human
colorectal cancer progression. Cancer Sci. 112:2692–2704. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma J, Liu L, Che G, Yu N, Dai F and You Z:
The M1 form of tumor-associated macrophages in non-small cell lung
cancer is positively associated with survival time. BMC Cancer.
10:1122010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Edin S, Wikberg ML, Dahlin AM, Rutegård J,
Öberg Å, Oldenborg PA and Palmqvist R: The distribution of
macrophages with a M1 or M2 phenotype in relation to prognosis and
the molecular characteristics of colorectal cancer. PLoS One.
7:e470452012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Yang K, Yang B, Wang R, Zhu Y and
Pan T: ANKRD22 participates in the proinflammatory activities of
macrophages in the colon cancer tumor microenvironment. Cancer
Immunol Immunother. 74:862025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nussbaum YI, Manjunath Y, Kaifi JT, Warren
W and Mitchem J: Analysis of tumor-associated macrophages'
heterogeneity in colorectal cancer patients using single-cell
RNA-seq data. J Clin Oncol. 40 (4_suppl):S1462025. View Article : Google Scholar
|
|
31
|
Liang Y, Li J, Yuan Y, Ju H, Liao H, Li M,
Liu Y, Yao Y, Yang L, Li T and Lei X: Exosomal miR-106a-5p from
highly metastatic colorectal cancer cells drives liver metastasis
by inducing macrophage M2 polarization in the tumor
microenvironment. J Exp Clin Cancer Res. 43:2812024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Q, Yang C, Wang S, Shi D, Wei C, Song
J, Lin X, Dou R, Bai J, Xiang Z, et al: Wnt5a-induced M2
polarization of tumor-associated macrophages via IL-10 promotes
colorectal cancer progression. Cell Commun Signal. 18:512020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu
Y, Zhang Z, Cai S, Xu Y, Li X, et al: Tumor-derived exosomal
miR-934 induces macrophage M2 polarization to promote liver
metastasis of colorectal cancer. J Hematol Oncol. 13:1562020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Z, Xu Y, Shao B, Dang P, Hu S, Sun H,
Chen C, Wang C, Liu J, Liu Y and Hu J: Exosomal circPOLQ promotes
macrophage M2 polarization via activating Il-10/STAT3 axis in a
colorectal cancer model. J Immunother Cancer. 12:e0084912024.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang C, Dou R, Wei C, Liu K, Shi D, Zhang
C, Liu Q, Wang S and Xiong B: Tumor-derived exosomal
microRNA-106b-5p activates EMT-cancer cell and M2-subtype tam
interaction to facilitate CRC metastasis. Mol Ther. 29:2088–2107.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu Y, Xiao Y, Ding Y, Ran R, Wei K, Tao S,
Mao H, Wang J, Pang S, Shi J, et al: Colorectal cancer cell-derived
exosomal miRNA-372-5p induces immune escape from colorectal cancer
via PTEN/AKT/NF-κB/PD-L1 pathway. Int Immunopharmacol. 143((Pt 1)):
1132612024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu X, Liang R, Lan T, Ding D, Huang S,
Shao J, Zheng Z, Chen T, Huang Y, Liu J, et al: Tumor-associated
macrophage-specific CD155 contributes to M2-phenotype transition,
immunosuppression, and tumor progression in colorectal cancer. J
Immunother Cancer. 10:e0042192022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang D, Wang X, Si M, Yang J, Sun S, Wu H,
Cui S, Qu X and Yu X: Exosome-encapsulated miRNAS contribute to
CXCL12/CXCR4-induced liver metastasis of colorectal cancer by
enhancing M2 polarization of macrophages. Cancer Lett. 474:36–52.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hardbower DM, Coburn LA, Asim M, Singh K,
Sierra JC, Barry DP, Gobert AP, Piazuelo MB, Washington MK and
Wilson KT: EGFR-mediated macrophage activation promotes
colitis-associated tumorigenesis. Oncogene. 36:3807–3819. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP,
Wu C and Zheng L: Activated monocytes in peritumoral stroma of
hepatocellular carcinoma foster immune privilege and disease
progression through PD-L1. J Exp Med. 206:1327–1337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu X, Qian J, Ding L, Pan C, Liu X, Wu Q,
Wang S, Liu J, Shang M, Su R, et al: Galectin-1-induced tumor
associated macrophages repress antitumor immunity in hepatocellular
carcinoma through recruitment of tregs. Adv Sci (Weinh).
12:e24087882025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mantovani A and Allavena P: The
interaction of anticancer therapies with tumor-associated
macrophages. J Exp Med. 212:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Klug F, Prakash H, Huber PE, Seibel T,
Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et
al: Low-dose irradiation programs macrophage differentiation to an
iNOS+/M1 phenotype that orchestrates effective T cell
immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gordon SR, Maute RL, Dulken BW, Hutter G,
George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al:
PD-1 expression by tumour-associated macrophages inhibits
phagocytosis and tumour immunity. Nature. 545:495–499. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Byrne KT, Betts CB, Mick R, Sivagnanam S,
Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C,
et al: Neoadjuvant selicrelumab, an agonist CD40 antibody, induces
changes in the tumor microenvironment in patients with resectable
pancreatic cancer. Clin Cancer Res. 27:4574–4586. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dowlati A, Harvey RD, Carvajal RD, Hamid
O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka
AM, et al: LY3022855, an anti-colony stimulating factor-1 receptor
(CSF-1R) monoclonal antibody, in patients with advanced solid
tumors refractory to standard therapy: Phase 1 dose-escalation
trial. Invest New Drugs. 39:1057–1071. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Voissière A, Gomez-Roca C, Chabaud S,
Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux
I, Eberst L, et al: The CSF-1R inhibitor pexidartinib affects
FLT3-dependent DC differentiation and may antagonize durvalumab
effect in patients with advanced cancers. Sci Transl Med.
16:eadd18342024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brana I, Calles A, LoRusso PM, Yee LK,
Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J and
Calvo E: Carlumab, an anti-C-C chemokine ligand 2 monoclonal
antibody, in combination with four chemotherapy regimens for the
treatment of patients with solid tumors: An open-label, multicenter
phase 1b study. Target Oncol. 10:111–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gomez-Roca CA, Italiano A, Le Tourneau C,
Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat
D, Cannarile MA, et al: Phase I study of emactuzumab single agent
or in combination with paclitaxel in patients with
advanced/metastatic solid tumors reveals depletion of
immunosuppressive M2-like macrophages. Ann Oncol. 30:1381–1392.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Falchook GS, Peeters M, Rottey S, Dirix
LY, Obermannova R, Cohen JE, Perets R, Frommer RS, Bauer TM, Wang
JS, et al: A phase 1a/1b trial of CSF-1R inhibitor ly3022855 in
combination with durvalumab or tremelimumab in patients with
advanced solid tumors. Invest New Drugs. 39:1284–1297. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nywening TM, Wang-Gillam A, Sanford DE,
Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA,
Yano M, et al: Targeting tumour-associated macrophages with CCR2
inhibition in combination with FOLFIRINOX in patients with
borderline resectable and locally advanced pancreatic cancer: A
single-centre, open-label, dose-finding, non-randomised, phase 1b
trial. Lancet Oncol. 17:651–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cannarile MA, Weisser M, Jacob W, Jegg AM,
Ries CH and Rüttinger D: Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer.
5:532017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qu T, Li B and Wang Y: Targeting
CD47/SIRPα as a therapeutic strategy, where we are and where we are
headed. Biomark Res. 10:202022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Eng C, Lakhani NJ, Philip PA, Schneider C,
Johnson B, Kardosh A, Chao MP, Patnaik A, Shihadeh F, Lee Y, et al:
A phase 1b/2 study of the anti-CD47 antibody magrolimab with
cetuximab in patients with colorectal cancer and other solid
tumors. Target Oncol. 20:519–530. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yamada-Hunter SA, Theruvath J, McIntosh
BJ, Freitas KA, Lin F, Radosevich MT, Leruste A, Dhingra S,
Martinez-Velez N, Xu P, et al: Engineered CD47 protects T cells for
enhanced antitumour immunity. Nature. 630:457–465. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Reiss KA, Angelos MG, Dees EC, Yuan Y,
Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, et
al: Car-macrophage therapy for HER2-overexpressing advanced solid
tumors: A phase 1 trial. Nat Med. 31:1171–1182. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tan PB, Verschoor YL, van den Berg JG,
Balduzzi S, Kok NFM, Ijsselsteijn ME, Moore K, Jurdi A, Tin A,
Kaptein P, et al: Neoadjuvant immunotherapy in
mismatch-repair-proficient colon cancers. Nature. 648:726–735.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang F, Chen G, Qiu M, Ma J, Mo X, Liu H,
Li Y, Ding P, Wan X, Hu Y, et al: Neoadjuvant treatment of IBI310
plus sintilimab in locally advanced MSI-H/DMMR colon cancer: A
randomized phase 1b study. Cancer Cell. 43:1958–1967.e2. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang X, Wang J, Wang G, Zhang Y, Fan Q,
Lu C, Hu C, Sun M, Wan Y, Sun S, et al: First-line sugemalimab plus
chemotherapy for advanced gastric cancer: The gemstone-303
randomized clinical trial. JAMA. 333:1305–1314. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ohtani Y, Ross K, Dandekar A, Gabbasov R
and Klichinsky M: 128 development of an M1-polarized, non-viral
chimeric antigen receptor macrophage (car-m) platform for cancer
immunotherapy. Journal for ImmunoTherapy of Cancer. 8 (Suppl
3):doi.org/10.1136/jitc-2020-SITC2020.0128. 2020.
|
|
63
|
Razak AR, Cleary JM, Moreno V, Boyer M,
Aller EC, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, et al:
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1
receptor antibody, in combination with pembrolizumab in adults with
advanced solid tumors. J Immunother Cancer. 8:e0010062020.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Spierenburg G, van der Heijden L, van
Langevelde K, Szuhai K, Bovée JVGM, van de Sande MAJ and Gelderblom
H: Tenosynovial giant cell tumors (TGCT): Molecular biology, drug
targets and non-surgical pharmacological approaches. Expert Opin
Ther Targets. 26:333–345. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Golstein P and Griffiths GM: An early
history of T cell-mediated cytotoxicity. Nat Rev Immunol.
18:527–535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pei S, Pollyea DA, Gustafson A,
Minhajuddin M, Stevens BM, Ye HY, Inguva A, Amaya ML, Krug A, Jones
CL, et al: Developmental plasticity of acute myeloid leukemia
mediates resistance to venetoclax-based therapy. Blood. 134
(Suppl_1):S1852019. View Article : Google Scholar
|
|
67
|
Li X, Gruosso T, Zuo D, Omeroglu A,
Meterissian S, Guiot MC, Salazar A, Park M and Levine H:
Infiltration of CD8(+) T cells into tumor cell clusters in
triple-negative breast cancer. Proc Natl Acad Sci USA.
116:3678–3687. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang L, Shi YC, Yang YX, Wang ZG, Wang SS
and Zhang H: Association of T lymphocyte subset counts with the
clinical features of colorectal cancer. J Nutr Oncol. 8:178–185.
2023. View Article : Google Scholar
|
|
70
|
Doering TA, Crawford A, Angelosanto JM,
Paley MA, Ziegler CG and Wherry EJ: Network analysis reveals
centrally connected genes and pathways involved in CD8+ T cell
exhaustion versus memory. Immunity. 37:1130–1144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Angelosanto JM, Blackburn SD, Crawford A
and Wherry EJ: Progressive loss of memory T cell potential and
commitment to exhaustion during chronic viral infection. J Virol.
86:8161–8170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Im SJ, Hashimoto M, Gerner MY, Lee J,
Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al:
Defining CD8+ T cells that provide the proliferative burst after
PD-1 therapy. Nature. 537:417–421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Alfei F and Zehn D: T cell exhaustion: An
epigenetically imprinted phenotypic and functional makeover. Trends
Mol Med. 23:769–771. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Baitsch L, Baumgaertner P, Devêvre E,
Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke
B, Romero P, et al: Exhaustion of tumor-specific CD8+ T
cells in metastases from melanoma patients. J Clin Invest.
121:2350–2360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Odorizzi PM, Pauken KE, Paley MA, Sharpe A
and Wherry EJ: Genetic absence of PD-1 promotes accumulation of
terminally differentiated exhausted Cd8+ T cells. J Exp Med.
212:1125–1137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chen Y, Wang D, Li Y, Qi L, Si W, Bo Y,
Chen X, Ye Z, Fan H, Liu B, et al: Spatiotemporal single-cell
analysis decodes cellular dynamics underlying different responses
to immunotherapy in colorectal cancer. Cancer Cell.
42:1268–1285.e7. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang
F, Wang Y, Wei J, Chen H, Tartarone A, et al: Progenitor-like
exhausted SPRY1(+)CD8(+) t cells potentiate responsiveness to
neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma.
Cancer Cell. 41:1852–1870.e9. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang
C, Bai G, Yang L, Fan H, Chen Y, et al: A single-cell atlas reveals
immune heterogeneity in anti-PD-1-treated non-small cell lung
cancer. Cell. 188:3081–3096.e19. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kim YJ, Park SJ and Broxmeyer HE:
Phagocytosis, a potential mechanism for myeloid-derived suppressor
cell regulation of CD8+ T cell function mediated through programmed
cell death-1 and programmed cell death-1 ligand interaction. J
Immunol. 187:2291–2301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tanaka A and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Cell Res. 27:109–118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ma S, Dahabieh MS, Mann TH, Zhao S,
McDonald B, Song WS, Chung HK, Farsakoglu Y, Garcia-Rivera L,
Hoffmann FA, et al: Nutrient-driven histone code determines
exhausted CD8(+) T cell fates. Science. 387:eadj30202025.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li J, Wu C, Hu H, Qin G, Wu X, Bai F,
Zhang J, Cai Y, Huang Y, Wang C, et al: Remodeling of the immune
and stromal cell compartment by pd-1 blockade in mismatch
repair-deficient colorectal cancer. Cancer Cell. 41:1152–1169.e7.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Borràs DM, Verbandt S, Ausserhofer M,
Sturm G, Lim J, Verge GA, Vanmeerbeek I, Laureano RS, Govaerts J,
Sprooten J, et al: Single cell dynamics of tumor specificity vs
bystander activity in CD8(+) T cells define the diverse immune
landscapes in colorectal cancer. Cell Discov. 9:1142023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Donia M, Andersen R, Kjeldsen JW, Fagone
P, Munir S, Nicoletti F, Andersen MH, Straten PT and Svane IM:
Aberrant expression of MHC class II in melanoma attracts
inflammatory tumor-specific CD4+ T- cells, which dampen CD8+ T-cell
antitumor reactivity. Cancer Res. 75:3747–3759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Borst J, Ahrends T, Bąbała N, Melief CJM
and Kastenmüller W: CD4(+) T cell help in cancer immunology and
immunotherapy. Nat Rev Immunol. 18:635–647. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ahrends T, Spanjaard A, Pilzecker B,
Bąbała N, Bovens A, Xiao Y, Jacobs H and Borst J: CD4(+) T cell
help confers a cytotoxic T cell effector program including
coinhibitory receptor downregulation and increased tissue
invasiveness. Immunity. 47:848–861.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shamoun L, Skarstedt M, Andersson RE,
Wågsäter D and Dimberg J: Association study on IL-4, IL-4Rα and
Il-13 genetic polymorphisms in swedish patients with colorectal
cancer. Clin Chim Acta. 487:101–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li W, Chen F, Gao H, Xu Z, Zhou Y, Wang S,
Lv Z, Zhang Y, Xu Z, Huo J, et al: Cytokine concentration in
peripheral blood of patients with colorectal cancer. Front Immunol.
14:11755132023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ivanov II, McKenzie BS, Zhou L, Tadokoro
CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR: The orphan
nuclear receptor rorgammat directs the differentiation program of
proinflammatory IL-17+ T helper cells. Cell. 126:1121–1133. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Huber S, Gagliani N, Zenewicz LA, Huber
FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et
al: IL-22BP is regulated by the inflammasome and modulates
tumorigenesis in the intestine. Nature. 491:259–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kryczek I, Wei S, Szeliga W, Vatan L and
Zou W: Endogenous IL-17 contributes to reduced tumor growth and
metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bai Y, Li T, Wang Q, You W, Yang H, Xu X,
Li Z, Zhang Y, Yan C, Yang L, et al: Shaping immune landscape of
colorectal cancer by cholesterol metabolites. EMBO Mol Med.
16:334–360. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
De Simone V, Pallone F, Monteleone G and
Stolfi C: Role of TH17 cytokines in the control of
colorectal cancer. Oncoimmunology. 2:e266172013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
96
|
Sayour EJ, McLendon P, McLendon R, De Leon
G, Reynolds R, Kresak J, Sampson JH and Mitchell DA: Increased
proportion of FoxP3+ regulatory T cells in tumor infiltrating
lymphocytes is associated with tumor recurrence and reduced
survival in patients with glioblastoma. Cancer Immunol Immunother.
64:419–427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: Foxp3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zi R, Zhao X, Liu L, Wang Y, Zhang R, Bian
Z, Jiang H, Liu T, Sun Y, Peng H, et al: Metabolic-immune
suppression mediated by the SIRT1-CX3CL1 axis induces functional
enhancement of regulatory T cells in colorectal carcinoma. Adv Sci
(Weinh). 12:e24047342025. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X,
Shao Q, Zhou B, Zhou H, Wei S, et al: Tumor metabolite lactate
promotes tumorigenesis by modulating MOESIN lactylation and
enhancing TGF-beta signaling in regulatory T cells. Cell Rep.
39:1109862022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Adamczyk A, Pastille E, Kehrmann J, Vu VP,
Geffers R, Wasmer MH, Kasper S, Schuler M, Lange CM, Muggli B, et
al: GPR15 facilitates recruitment of regulatory T cells to promote
colorectal cancer. Cancer Res. 81:2970–2982. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Akkaya M, Kwak K and Pierce SK: B cell
memory: Building two walls of protection against pathogens. Nat Rev
Immunol. 20:229–238. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Choi IK, Wang Z, Ke Q, Hong M, Paul DW Jr,
Fernandes SM, Hu Z, Stevens J, Guleria I, Kim HJ, et al: Mechanism
of EBV inducing anti-tumour immunity and its therapeutic use.
Nature. 590:157–162. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Manfroi B and Fillatreau S: Regulatory B
cells gain muscles with a leucine-rich diet. Immunity. 55:970–972.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Murakami Y, Saito H, Shimizu S, Kono Y,
Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Ashida K, Sakabe
T, et al: Increased regulatory B cells are involved in immune
evasion in patients with gastric cancer. Sci Rep. 9:130832019.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Griss J, Bauer W, Wagner C, Simon M, Chen
M, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T,
Bock C, et al: B cells sustain inflammation and predict response to
immune checkpoint blockade in human melanoma. Nat Commun.
10:41862019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mao H, Pan F, Wu Z, Wang Z, Zhou Y, Zhang
P, Gou M and Dai G: Colorectal tumors are enriched with regulatory
plasmablasts with capacity in suppressing T cell inflammation. Int
Immunopharmacol. 49:95–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liao Y, Zhuo X, Huang Y, Xu H, Hao Z,
Huang L, Zheng H and Zhou J: A SENP7-SIRT1-IL-10 axis driven by
DeSUMOylation promotes breg differentiation and immune evasion in
colorectal cancer. Int J Biol Sci. 22:111–125. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Hou D, Castro B, Dapash M, Rashidi A,
Zhang P, Han Y, Lopez-Rosas A, Lesniak M, Miska J and Chang C:
Immu-36. B cell-vaccine elicits long term immunity against
glioblastoma via activation and differentiation of tumor-specific
CD8+ memory T cells. Neuro Oncol. 23 (Suppl_6):vi100.
2021. View Article : Google Scholar
|
|
109
|
Irimia RM, Gerke MB, Thakar M, Ren Z,
Helmenstine E, Imus PH, Ghiaur G, Leone R and Gocke GB: CD38 is a
key regulator of tumor growth by modulating the metabolic signature
of malignant plasma cells. Blood. 138 (Suppl 1):S26522021.
View Article : Google Scholar
|
|
110
|
Malik H, Buelow B, Rangaswamy U,
Balasubramani A, Boudreau A, Dang K, Davison L, Aldred SF, Harris
KM, Iyer S, Jorgensen B, Pham D, Prabhakar K, Schellenberger U,
Ugamraj H, Trinklein N and Van Schooten W: Tnb-486, a novel fully
human bispecific CD19 × CD3 antibody that kills CD19-positive tumor
cells with minimal cytokine secretion. Blood. 134 (Suppl_1):S4070.
2019. View Article : Google Scholar
|
|
111
|
Wang W, Zhong Y, Zhuang Z, Xie J, Lu Y,
Huang C, Sun Y, Wu L, Yin J, Yu H, et al: Multiregion single-cell
sequencing reveals the transcriptional landscape of the immune
microenvironment of colorectal cancer. Clin Transl Med.
11:e2532021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Nicolai CJ and Raulet DH: Killer cells add
fire to fuel immunotherapy. Science. 368:943–944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Dixon K, Hullsiek R, Snyder K, Davis Z,
Khaw M, Lee T, Chu HY, Abujarour R, Dinella J, Rogers P, et al:
Engineered iPSC-derived NK cells expressing recombinant CD64 for
enhanced ADCC. Blood. 136 (Suppl 1):S10–S11. 2020. View Article : Google Scholar
|
|
114
|
Fauriat C, Long EO, Ljunggren HG and
Bryceson YT: Regulation of human NK-cell cytokine and chemokine
production by target cell recognition. Blood. 115:2167–2176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Liu YJ, Han M, Li JP, Zeng SH, Ye QW, Yin
ZH, Liu SL and Zou X: An analysis regarding the association between
connexins and colorectal cancer (CRC) tumor microenvironment. J
Inflamm Res. 15:2461–2476. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Yang L, Yi J, He W, Kong P, Xie Q, Jin Y,
Xiong Z and Xia L: Death receptors 4/5 mediate tumour sensitivity
to natural killer cell-mediated cytotoxicity in mismatch repair
deficient colorectal cancer. Br J Cancer. 131:334–346. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Otegbeye F, Ojo E, Moreton S, Mackowski N,
Lee DA, de Lima M and Wald DN: Inhibiting TGF-beta signaling
preserves the function of highly activated, in vitro expanded
natural killer cells in AML and colon cancer models. PLoS One.
13:e01913582018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Vuletić A, Martinović KM, Miletić NT,
Zoidakis J, Castellvi-Bel S and Čavić M: Cross-talk between tumor
cells undergoing epithelial to mesenchymal transition and natural
killer cells in tumor microenvironment in colorectal cancer. Front
Cell Dev Biol. 9:7500222021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Tang S, Fu H, Xu Q and Zhou Y: Mir-20a
regulates sensitivity of colorectal cancer cells to NK cells by
targeting mica. Biosci Rep. 39:BSR201806952019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lin A, Ye P, Li Z, Jiang A, Liu Z, Cheng
Q, Zhang J and Luo P: Natural killer cell immune checkpoints and
their therapeutic targeting in cancer treatment. Research (Wash
DC). 8:07232025.PubMed/NCBI
|
|
121
|
Lupo K and Matosevic S: 123 natural killer
cells engineered with an inducible, responsive genetic construct
targeting tigit and CD73 to relieve immunosuppression within the
gbm microenvironment. Journal for ImmunoTherapy of Cancer. 8 (Suppl
3):doi.org/10.1136/jitc-2020-SITC2020.0123. 2020.PubMed/NCBI
|
|
122
|
Strassheimer F, Strecker MI, Alekseeva T,
Macas J, Demes MC, Mildenberger IC, Tonn T, Wild PJ, Sevenich L,
Reiss Y, et al: Os12.6.A combination therapy of CAR-NK-cells and
anti-pd-1 results in high efficacy against advanced-stage
glioblastoma in a syngeneic mouse model and induces protective
anti-tumor immunity in vivo. Neuro Oncol. 23 (Suppl_2):ii152021.
View Article : Google Scholar
|
|
123
|
Kong R, Liu B, Wang H, Lu T and Zhou X:
CAR-NK cell therapy: Latest updates from the 2024 ASH annual
meeting. J Hematol Oncol. 18:222025. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Duan J, Zhao S, Duan Y, Sun D, Zhang G, Yu
D, Lou Y, Liu H, Yang S, Liang X, et al: Mnox nanoenzyme
armed CAR-NK cells enhance solid tumor immunotherapy by alleviating
the immunosuppressive microenvironment. Adv Healthc Mater.
13:e23039632024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang W, Liu Y, He Z, Li L, Liu S, Jiang M,
Zhao B, Deng M, Wang W, Mi X, et al: Breakthrough of solid tumor
treatment: CAR-NK immunotherapy. Cell Death Discov. 10:402024.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Reizis B: Plasmacytoid dendritic cells:
Development, regulation, and function. Immunity. 50:37–50. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wculek SK, Cueto FJ, Mujal AM, Melero I,
Krummel MF and Sancho D: Dendritic cells in cancer immunology and
immunotherapy. Nat Rev Immunol. 20:7–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Jhunjhunwala S, Hammer C and Delamarre L:
Antigen presentation in cancer: Insights into tumour immunogenicity
and immune evasion. Nat Rev Cancer. 21:298–312. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Klempner SJ, Cecchini M, Khushman M,
Kummar S, Pelster M, Rodon J, Sharma S, Yaeger R, Rojo J, Wells AL,
et al: Abstract B031: A phase 1/2 trial of fog-001, a
first-in-class direct β-catenin:Tcf4 inhibitor, preliminary safety
and efficacy in patients with solid tumors bearing wnt
pathway-activating mutations (WPAM+). Mol Cancer Ther. 24
(10_Suppl):B0312025. View Article : Google Scholar
|
|
130
|
Suryawanshi A, Hussein MS, Prasad PD and
Manicassamy S: Wnt signaling cascade in dendritic cells and
regulation of anti-tumor immunity. Front Immunol. 11:1222020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Dhodapkar MV, Dhodapkar KM and Palucka AK:
Interactions of tumor cells with dendritic cells: Balancing
immunity and tolerance. Cell Death Differ. 15:39–50. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Itai YS, Barboy O, Salomon R, Bercovich A,
Xie K, Winter E, Shami T, Porat Z, Erez N, Tanay A, et al:
Bispecific dendritic-T cell engager potentiates anti-tumor
immunity. Cell. 187:375–389.e18. 2024. View Article : Google Scholar
|
|
133
|
Aznar MA, Planelles L, Perez-Olivares M,
Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E,
Lopez-Casas P, et al: Immunotherapeutic effects of intratumoral
nanoplexed poly I:C. J Immunother Cancer. 7:1162019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
He F, Wu Z, Liu C, Zhu Y, Zhou Y, Tian E,
Rosin-Arbesfeld R, Yang D, Wang MW and Zhu D: Targeting BCL9/BCL9L
enhances antigen presentation by promoting conventional type 1
dendritic cell (cDC1) activation and tumor infiltration. Signal
Transduct Target Ther. 9:1392024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Singer M, Valerin J, Zhang Z, Zhang Z,
Dayyani F, Yaghmai V, Choi A, Imagawa D and Abi-Jaoudeh N:
Promising cellular immunotherapy for colorectal cancer using
classical dendritic cells and natural killer T cells. Cells.
14:1662025. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Passardi A, Sullo FG, Bittoni A, Matteucci
L, De Rosa F, Bulgarelli J, Tazzari M, Petrini M, Scarpi E, Testoni
S, et al: CombiCoR-Vax trial: Study protocol for a phase II,
single-arm, multicenter trial of sequential pembrolizumab plus
dendritic cell vaccine followed by trifluridine/tipiracil and
bevacizumab in refractory microsatellite-stable metastatic
colorectal cancer. BMC Cancer. 25:19212025. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Guo FF and Cui JW: The role of neutrophils
in cancer development. Journal of Nutritional Oncology. 4:85–90.
2019.https://journals.lww.com/jno/Fulltext/2019/05150/The_Role_of_Neutrophils_in_Cancer_Development.5.aspx
View Article : Google Scholar
|
|
138
|
Peng H, Shen J, Long X, Zhou X, Zhang J,
Xu X, Huang T, Xu H, Sun S, Li C, et al: Local release of TGF-β
inhibitor modulates tumor-associated neutrophils and enhances
pancreatic cancer response to combined irreversible electroporation
and immunotherapy. Adv Sci (Weinh). 9:e21052402022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Giese MA, Hind LE and Huttenlocher A:
Neutrophil plasticity in the tumor microenvironment. Blood.
133:2159–2167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Yang L, Liu L, Zhang R, Hong J, Wang Y,
Wang J, Zuo J, Zhang J, Chen J and Hao H: IL-8 mediates a positive
loop connecting increased neutrophil extracellular traps (NETs) and
colorectal cancer liver metastasis. J Cancer. 11:4384–4396. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yang L, Liu Q, Zhang X, Liu X, Zhou B,
Chen J, Huang D, Li J, Li H, Chen F, et al: DNA of neutrophil
extracellular traps promotes cancer metastasis via CCDC25. Nature.
583:133–138. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Tohme S, Yazdani HO, Al-Khafaji AB, Chidi
AP, Loughran P, Mowen K, Wang Y, Simmons RL, Huang H and Tsung A:
Neutrophil extracellular traps promote the development and
progression of liver metastases after surgical stress. Cancer Res.
76:1367–1380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wang X, He S, Gong X, Lei S, Zhang Q,
Xiong J and Liu Y: Neutrophils in colorectal cancer: Mechanisms,
prognostic value, and therapeutic implications. Front Immunol.
16:15386352025. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Yuan Y, Chen YF, Liu XM, Hu Y, Hao S and
Dai XY: Analysis of risk factors and prognostic prediction in
advanced colorectal cancer undergoing immunotherapy combined with
targeted therapy. Front Med (Lausanne). 12:16404692025. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zhu T, Zou X, Yang C, Li L, Wang B, Li R,
Li H, Xu Z, Huang D and Wu Q: Neutrophil extracellular traps
promote gastric cancer metastasis by inducing
epithelial-mesenchymal transition. Int J Med. 48:1272021.
|
|
146
|
Cheng Y, Mo F, Li Q, Han X, Shi H, Chen S,
Wei Y and Wei X: Targeting CXCR2 inhibits the progression of lung
cancer and promotes therapeutic effect of cisplatin. Mol Cancer.
20:622021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Chu X, Li X, Zhang Y, Dang G, Miao Y, Xu
W, Wang J, Zhang Z and Cheng S: Integrative single-cell analysis of
human colorectal cancer reveals patient stratification with
distinct immune evasion mechanisms. Nat Cancer. 5:1409–1426. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Oliveira MF, Romero JP, Chung M, Williams
SR, Gottscho AD, Gupta A, Pilipauskas SE, Mohabbat S, Raman N,
Sukovich DJ, et al: High-definition spatial transcriptomic
profiling of immune cell populations in colorectal cancer. Nat
Genet. 57:1512–1523. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhang L, Li Z, Skrzypczynska KM, Fang Q,
Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A, et al:
Single-cell analyses inform mechanisms of myeloid-targeted
therapies in colon cancer. Cell. 181:442–459.e29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu
K, Hu X, Bu Z, Peng J, Ren X and Zhang Z: Immune phenotypic linkage
between colorectal cancer and liver metastasis. Cancer Cell.
40:424–437.e5. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D,
Cheng Y, Huang S, Liu Y, Jiang S, et al: Spatiotemporal immune
landscape of colorectal cancer liver metastasis at single-cell
level. Cancer Discov. 12:134–153. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zhang L, Yu X, Zheng L, Zhang Y, Li Y,
Fang Q, Gao R, Kang B, Zhang Q, Huang JY, et al: Lineage tracking
reveals dynamic relationships of T cells in colorectal cancer.
Nature. 564:268–272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Feng Y, Ma W, Zang Y, Guo Y, Li Y, Zhang
Y, Dong X, Liu Y, Zhan X, Pan Z, et al: Spatially organized
tumor-stroma boundary determines the efficacy of immunotherapy in
colorectal cancer patients. Nat Commun. 15:102592024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Massagué J and Sheppard D: TGF-β signaling
in health and disease. Cell. 186:4007–4037. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Sikic BI, Lakhani N, Patnaik A, Shah SA,
Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S,
Papadopoulos K, et al: First-in-human, first-in-class phase I trial
of the anti-CD47 antibody Hu5f9-G4 in patients with advanced
cancers. J Clin Oncol. 37:946–953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Pyo DH, Hong HK, Lee WY and Cho YB:
Patient-derived cancer modeling for precision medicine in
colorectal cancer: Beyond the cancer cell line. Cancer Biol Ther.
21:495–502. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Balaban E and Cohen M: Decoding
multicellular interaction networks-a new horizon in tumor
microenvironment research. Mol Oncol. 19:957–960. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Gomez-Roca C, Cassier P, Zamarin D,
Machiels JP, Gracia JL, Hodi FS, Taus A, Garcia M, Boni V, Eder JP,
et al: Anti-CSF-1R emactuzumab in combination with anti-PD-L1
atezolizumab in advanced solid tumor patients naïve or experienced
for immune checkpoint blockade. J Immunother Cancer.
10:e0040762022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wagner SJ, Reisenbüchler D, West NP,
Niehues JM, Zhu J, Foersch S, Veldhuizen GP, Quirke P, Grabsch HI,
van den Brandt PA, et al: Transformer-based biomarker prediction
from colorectal cancer histology: A large-scale multicentric study.
Cancer Cell. 41:1650–1661.e4. 2023. View Article : Google Scholar : PubMed/NCBI
|
